Wound healing adverse events in kidney transplant recipients receiving everolimus with reduced calcineurin inhibitor exposure or current standard-of-care: insights from the 24-month TRANSFORM study-Reference-Cited by-同舟云学术

Wound healing adverse events in kidney transplant recipients receiving everolimus with reduced calcineurin inhibitor exposure or current standard-of-care: insights from the 24-month TRANSFORM study

Published:2020-07-20 Issue:10 Volume:19 Page:1339-1348
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Citterio Franco¹,Henry Mitchell²,Kim Dean Y³,Kim Myoung Soo⁴,Han Duck-Jong⁵,Kenmochi Takashi⁶,Mor Eytan⁷,Tisone Giuseppe⁸,Bernhardt Peter⁹,Hernandez Gutierrez Maria Pilar⁹,Watarai Yoshihiko¹⁰

Affiliation:

1. Department of Surgery, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy

2. Department of Surgery, The Comprehensive Transplant Center, The Ohio State University, Wexner Medical Center, Columbus, OH, USA

3. Department of Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, USA

4. Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea

5. Department of Surgery, Asan Medical Center, Seoul, Republic of South Korea

6. Department of Transplant Surgery, Fujita Health University, Toyoake, Japan

7. Department of Surgery, Transplant Center at Sheba Medical Center, Ramat-Gan, Israel

8. Department of Surgery HPB and Transplant Unit, University of Tor Vergata, Rome, Italy

9. Department of Research and Development, Novartis Pharma AG, Basel, Switzerland

10. Department of Transplant Surgery and Nephrology, Nagoya Daini Red Cross Hospital, Nagoya-City, Japan

Funder

Novartis Pharma AG, Basel, Switzerland. Medical writing support was funded by Novartis

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2020.1792441

Reference22 articles.

1. Safety of mTOR inhibitors in adult solid organ transplantation

2. Wound Healing Complications and the Use of Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation

3. Everolimus Plus Reduced-Exposure CsA versus Mycophenolic Acid Plus Standard-Exposure CsA in Renal-Transplant Recipients

4. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus inDe NovoRenal Transplant Recipients: 12-Month Data

5. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical outcomes of endovascular therapy for chronic limb-threatening ischemia in renal transplant recipients;Cardiovascular Intervention and Therapeutics;2024-09-03

2. Examining the Association between Immunosuppressants and Wound Healing: A Narrative Review;Advances in Skin & Wound Care;2024-05

3. Evaluation of T-Cell Immune Status of Reduced-Dose Cyclosporine and Everolimus Combination Therapy in Kidney Transplant Patients;Transplantation Proceedings;2023-05

4. The case for the therapeutic use of mechanistic/mammalian target of rapamycin (mTOR) inhibitors in xenotransplantation;Xenotransplantation;2023-04-07

5. Complications, demographics and hospital stay in organ transplant patients undergoing total hip arthroplasty - A national database study between 2016 and 2019;Journal of Orthopaedics;2022-11